“QIMR has an international reputation in immunology research and has worked closely with other Australian biotechnology companies to develop their programs through to clinical trials,” said Mr Don Home, CEO of Incitive. “We are delighted to undertake the research for our lead product with QIMR and are confident that we will see great results from this partnership,” Mr Home added.
The research program will generate a preclinical data package demonstrating CCS’s efficacy, potency, stability and safety. If the preclinical R&D program is successful it will provide the data package Incitive needs to pursue its licensing activities with major pharmaceutical companies. Such a package is a prerequisite to entering human clinical trials.
“I am delighted to see this technology further developed through the appropriate commercial channels. The translation of medical research into drug development is an exciting step and I look forward to the future progress of the project,” said QIMR scientist Dr Tracey Mynott
Dr Mynott and her team at QIMR discovered CCS while investigating the properties of bromelain, a crushed pineapple stem extract. They discovered that bromelain could block the activation of specific immune cells called T cells and thus could be of use to treat autoimmune disease.
Autoimmune disease is a result of a misdirected immune system where the body starts to attack itself. It can affect almost any part of the body, sometimes even affecting multiple parts at once. Approximately 20 percent of the population (or one in five people), suffers from autoimmune disease. Common autoimmune diseases include Type 1 diabetes, rheumatoid arthritis, asthma and graft-versus-host disease (GVHD).
About Incitive Limited
Incitive Ltd is a public unlisted Life Science company that aims to become a leader in the development of drugs that treat inflammation and auto-immune diseases. The primary target markets are tissue/organ transplantation and autoimmune disease. Incitive’s current product pipeline is novel and based on over ten years of international peer-reviewed research. The lead products include small molecule drugs and protein drugs, all aimed to treat diseases in areas of unmet clinical need.
The PerfoRx technology will be developed at the Peter MacCallum Cancer Centre in Melbourne University of Auckland Australia
More information: www.incitiveltd.com
About Queensland Institute of Medical Research
Established in 1945, QIMR is the largest medical research institutes in the southern hemisphere, and is internationally recognised for the quality of its research.
Originally formed to further the study of tropical diseases in North Queensland, QIMR has over its 60-year history broadened its scope to include the immunological, biological and molecular basis of a wide range of infectious diseases, cancers and other disorders.
QIMR's strategy is to create an integrated approach to biomedical research. In addition to state of the art research laboratories, QIMR also has facilities for the cGMP manufacture of cell-based and molecular therapies. Also, colocated within the Institute is a commercial Phase I/II clinical trials facility, called Q-Pharm, allowing QIMR scientists and external clients the extended and unique capability for taking research findings "from the bench to the bedside".